News from photocure A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 03, 2021, 01:18 ET Photocure ASA: Results for the fourth quarter of 2020

Photocure ASA (OSE: PHO) reports Hexvix®/Cysview® revenues of NOK 97.7 million in the fourth quarter of 2020 (Q4 2019: NOK 58.8). Product revenues...

Jan 26, 2021, 02:59 ET Photocure Partners with Asieris MediTech to Commercialize Hexvix in Mainland China and Taiwan

Photocure ASA (PHO:OSE): The Bladder Cancer Company focused on delivering transformative solutions to improve the lives of bladder cancer patients,...

Dec 07, 2020, 02:02 ET New abstracts on the use of Blue Light Cystoscopy with Cysview presented at SUO

Photocure ASA (OSE:PHO) today announced new data and analyses presented at the 21st Annual Meeting of the Society of Urologic Oncology (SUO)....

Nov 10, 2020, 01:32 ET Photocure ASA: Results for the third quarter of 2020

Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 49.6 million in the third quarter of 2020 (Q3 2019: NOK 51.1), with the U.S....

Oct 16, 2020, 01:49 ET New data analysis on Blue Light Cystoscopy efficiency presented at the virtual BLADDR 2020 congress

Photocure ASA (OSE:PHO) today announces a highlight from the BLADDR 2020 congress, a poster presentation on new findings from the Nordic Flexible BLC ...

Oct 05, 2020, 01:43 ET Photocure announces new Cevira patent in Europe

Photocure ASA (OSE:PHO) today announces that the European Patent Office (EPO) has granted patent EP 2983780 covering the commercial Cevira® device in ...

Aug 18, 2020, 01:12 ET Photocure ASA: Results for the second quarter and first half of 2020

Photocure ASA (OSE:PHO) reported Hexvix®/Cysview® revenues of 53.5 million in the second quarter of 2020 (Q2 2019: NOK 52.1), corresponding to growth ...

Aug 13, 2020, 06:03 ET Photocure appoints Genotests as exclusive partner for Hexvix in Chile

Photocure ASA (OSE: PHO), today announced the appointment of Genotests SpA as the exclusive distributor for the commercialization of Hexvix® in Chile....

Jul 08, 2020, 12:32 ET Photocure's Partner Asieris Received China NMPA's Approval to Start a Global Phase III Clinical Trial for APL-1702 (Cevira)

Asieris Pharmaceuticals (Asieris), a China-based biotech company with global aspirations to discover, develop and commercialize innovative drugs for...

Jul 01, 2020, 09:48 ET Photocure Appoints Susanne Strauss as Vice President and General Manager of Europe

Photocure ASA (OSE:PHO), today announced the appointment of Susanne Strauss as Vice President and General Manager of Europe, effective 1 July 2020....

Jun 11, 2020, 02:14 ET Photocure Enters into Final Agreement to Regain Worldwide Rights of Hexvix

Reference is made to the OSE notification 27 April 2020 from Photocure ASA (PHO: OSE) regarding the return of Hexvix® sales, marketing and...

Jun 10, 2020, 12:29 ET Photocure ASA - Annual General Meeting Held

Photocure ASA (OSE: PHO), held its annual general meeting on 10 June 2020 at 17:00 hours (CET). All proposals were resolved as presented in the...

Jun 10, 2020, 01:18 ET Photocure ASA: Streaming Details for AGM and Announcement of Sustainability Report

Photocure ASA (OSE: PHO) today announces the company's first sustainability report, which will be presented at the Annual General Meeting (AGM) at...

May 16, 2020, 10:26 ET AUA Abstracts Further Support Role for Cysview® in the Office Setting

Photocure ASA (OSE: PHO) today announced key data was published by the 2020 American Urological Association (AUA) Annual Virtual Meeting. Three...

May 07, 2020, 01:15 ET Photocure ASA: Results for the First Quarter of 2020

Photocure ASA (OSE:PHO) announced the first quarter 2020 results in the trading update 27 April 2020, stating a revenue growth of 33% for the U.S....

Apr 27, 2020, 11:12 ET Photocure Regains Worldwide Rights of Hexvix

Photocure ASA (Photocure, PHO: OSE) has reached an agreement with Ipsen Pharma SAS (Ipsen) on key terms for the return of Hexvix sales, marketing and ...

Feb 27, 2020, 01:14 ET Photocure ASA: Results for the Fourth Quarter of 2019

Photocure ASA (OSE: PHO), today reported a revenue growth of 51% for the U.S. market in the fourth quarter of 2019, contributing to Hexvix/Cysview...

Nov 07, 2019, 01:13 ET Photocure ASA: Results for the Third Quarter of 2019

Photocure ASA (OSE: PHO), today reported a revenue growth of 42% in local currency for the U.S. market in the third quarter of 2019, contributing to...

Nov 05, 2019, 11:47 ET Photocure: Cysview® Reimbursement Further Improved From January 2020

Photocure ASA., (OSE: PHO), The United States Centers for Medicare and Medicaid Services (CMS) has released its Final Rule maintaining the...

May 06, 2019, 08:05 ET Expanded role for Cysview® (hexaminolevulinate HCl) in treating bladder cancer patients -- presented at the 2019 AUA Annual Meeting

Photocure ASA (OSE: PHO) today announced key data presented at the 2019 American Urological Association (AUA) Annual Meeting in Chicago. Session...

May 16, 2018, 08:00 ET Photocure Announces Blue Light Cystoscopy with Cysview® Now Available for Surveillance of Bladder Cancer

Photocure ASA (OSE: PHO), May 16, 2018, announced today the launch of Blue Light Cystoscopy (BLC™) with Cysview for a new indication of surveillance...

Feb 16, 2018, 09:00 ET Photocure Announces U.S. FDA Approval of New Indication for Blue Light Cystoscopy with Cysview®

Photocure ASA (OSE: PHO), announced today that the U.S. Food and Drug Administration (FDA) approved its supplemental new drug application (sNDA) to...

Jan 29, 2015, 04:12 ET New Data Provide Evidence that Hexvix® Can Improve the Overall Survival in Bladder Cancer Patients

In a retrospective study Hexvix fluorescence-guided bladder resection significantly improved overall survival and recurrence free survival compared...

Feb 04, 2011, 10:03 ET Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements

Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused in dermatology and cancer, today announced positive results from its...